Stamford, CT -- (SBWIRE) -- 01/14/2014 -- OTC Stock Picks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: IsoRay, Inc. (NYSEMKT:ISR), Mast Therapeutics Inc (NYSEMKT:MSTX), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Hemispherx BioPharma, Inc (NYSEMKT:HEB)
IsoRay, Inc. (NYSEMKT:ISR) opened the session at $0.59, trading in a range of $0.58 - $0.99. The stock showed a positive performance of +75.63% in the last trading session from its previous close of $0.28 and closed at $0.980. The stock traded on a volume of 9.82 million shares and the average volume of the stock remained 413,689 shares. IsoRay, Inc. (IsoRay) develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. IsoRay obtained clearance from the Food and Drug Association for treatment for all solid tumor applications using Cesium-131. Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; breast cancer; liver cancer; brain cancer; colorectal cancer; gynecological cancer; esophageal cancer, and pancreatic cancer.
For How Long ISR will Fight for Profitability? Read This Trend Analysis report
Mast Therapeutics Inc (NYSEMKT:MSTX) traded 25.62 million shares in the last business day while the average volume of the stock remained 2.01 million shares. The stock showed a positive movement of +56.60% to end at $0.830. The 52 week range of the stock remained $0.40 - $0.85. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease.
For How Long MSTX’s Gloss will Attract Investors? Find out via this report
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) reported 79.71 million shares were exchanged during the last trade, while the average volume is about 3.99 million shares. The stock escalated +40.35% and finished the day at $1.60. The beta of the stock is recorded at 1.83. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development.
For How Long RNN’s Gloss will Attract Investors? Find out via this report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) shares rose, +24.11 percent from its previous close of $0.28 to close at $0.347. Traded with volume of 9.00 million shares in the prior session and the average volume of the stock remained 2.11 million shares. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After The Recent Gain? Just Go Here and Find Out
About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.
Read full disclaimer at: http://otcstockpicks.net/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)